Exhibit 107

Calculation of Filing Fee Table

Form S-8

(Form Type)

Pieris Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

 

               
Security Type  

Security

Class

Title

  

Fee

Calculation

Rule

  

Amount

Registered

  

Proposed

Maximum

Offering

Price Per

Unit

  

Maximum

Aggregate

Offering

Price

  

Fee

Rate

  

Amount of

Registration

Fee

               
Equity   Common Stock, par value $0.001 per share   457(h)   6,000,000(1)    $0.237(2)    $1,422,000    $0.00011020    $156.70
               
Equity   Common Stock, par value $0.001 per share   457(h)   750,000(3)   $0.237(2)   $177,750   $0.00011020   $19.59
         
Total Offering Amount     $1,599,750      
         
Total Fee Offsets         —
         
Net Fee Due               $176.29

 

(1)

The number of shares of Common Stock, par value $0.001 per share (“Common Stock”), of Pieris Pharmaceuticals, Inc. (the “Registrant”) stated above consists of additional shares of Common Stock available for issuance under the Registrant’s 2020 Employee, Director and Consultant Equity Incentive Plan, as amended (the “2020 Plan”). The maximum number of shares which may be sold upon the exercise of options or issuance of stock-based awards granted under the 2020 Plan is subject to adjustment in accordance with certain anti-dilution and other provisions of the 2020 Plan. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement covers, in addition to the number of shares stated above, an indeterminate number of shares which may be subject to grant or otherwise issuable after the operation of any such anti-dilution and other provisions.

(2)

Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) promulgated under the Securities Act on the basis of the average of the high and the low price of Registrant’s Common Stock as reported on the Nasdaq Stock Market on August 4, 2023.

(3)

The number of shares of Common Stock stated above consists of up to 750,000 shares of Common Stock available for issuable under the Registrant’s 2023 Employee Stock Purchase Plan (the “2023 Plan”). The maximum number of shares which may be sold under the 2023 Plan is subject to adjustment in accordance with certain anti-dilution and other provisions of the 2023 Plan. Accordingly, pursuant to Rule 416 under the Securities Act, this registration statement covers, in addition to the number of shares stated above, an indeterminate number of shares which may be issuable after the operation of any such anti-dilution and other provisions.